Patent assignee · US · COMPANY

Abb Vie Inc.

824Patents
821Active
824Granted
64Portfolio score

Filing activity: Aug 26, 2005 → Oct 11, 2024 · 122 expiring within 5 years

Most-cited patents

PatentTitleAreaCited byStatus
US8963714B2 Tamper-evident packaging Physics 988 Active
US8420081B2 Antibody formulations and methods of making same Human Necessities 134 Active
US8883146B2 Protein formulations and methods of making same Chemistry; Metallurgy 90 Active
US8716450B2 Dual variable domain immunoglobulins and uses thereof Chemistry; Metallurgy 77 Active
US8822645B2 Prostaglandin E2 dual variable domain immunoglobulins and uses thereof Emerging Cross-Sectional Technologies 72 Active
US8563735B2 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 70 Active
US8586714B2 Dual variable domain immunoglobulins and uses thereof Chemistry; Metallurgy 65 Active
US8722855B2 Dual variable domain immunoglobulins and uses thereof Chemistry; Metallurgy 64 Active
US9163017B2 Anti-viral compounds Human Necessities 60 Active
US8785639B2 Substituted dihydropyrazolo[3,4-D]pyrrolo[2,3-B]pyridines and methods of use thereof Chemistry; Metallurgy 57 Active
US8546399B2 Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases Emerging Cross-Sectional Technologies 57 Active
US8586754B2 BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases Chemistry; Metallurgy 55 Active
US8962629B2 Tricyclic compounds Chemistry; Metallurgy 54 Active
US8663945B2 Methods of producing anti-TNF-alpha antibodies in mammalian cell culture Chemistry; Metallurgy 54 Active
US8895709B2 Isolation and purification of antibodies using protein A affinity chromatography Emerging Cross-Sectional Technologies 53 Active
US9029508B2 Dual variable domain immunoglobulins and uses thereof Emerging Cross-Sectional Technologies 53 Active
US8735546B2 Dual variable domain immunoglobulins and uses thereof Physics 53 Active
USD804806S1 Medication container General 51 Active
US8946395B1 Purification of proteins using hydrophobic interaction chromatography Chemistry; Metallurgy 50 Active
US9365579B2 Tricyclic compounds Chemistry; Metallurgy 49 Active
US8426422B2 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases Chemistry; Metallurgy 47 Active
US8546410B2 Heteroaryl-fused macrocyclic pyrimidine derivatives Chemistry; Metallurgy 45 Active
US9879019B2 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof Chemistry; Metallurgy 42 Active
US9879018B2 Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl and solid state forms thereof Chemistry; Metallurgy 42 Active
US8906646B2 Fed-batch method of making human anti-TNF-alpha antibody Chemistry; Metallurgy 42 Active

Source: USPTO / EPO open patent data. Counts and citation impact are objective bibliographic measures.